COMPANY

LAST TECHNOLOGY is considered as the main player in the design and manufacture of Infection Control equipment for the Pharmaceutical industry.

The headquarters of the company are located in the North East of Italy, nearby Venice. The plant uses renewable energies that are environmentally friendly (green power).All plant exhausts are pre-treated and recycled for being reused.

The quality-oriented philosophy as well as the production flexibility make LAST TECHNOLOGY focus on customizable, safe and reliable solutions. Its high performance equipment is innovatively designed for the prevention of infection throughout the inactivation of bacteria.

OUR DIVISIONS

Tailor made solutions

One size does not always fit all.

That is why we are specialized in providing the best suitable solutions for our customers’ needs.

Hover the images

Click on the images

GMP SOLUTIONS

UCW – Onco line Washing of surfaces contaminated with oncological drugs

Learn more

GMP SOLUTIONS

RSA Premium – 3 different processes in 1 chamber only 

Learn more

TS Terminal Sterilizer – Air + Steam Mixture or Overheated Water

Learn more

COMPLETE RANGE

RSA – GMP Regular Steam Autoclave

Learn More 


DHS – GMP Dry Heat Sterilizer 

Learn More 


DHS – GMP Dry Heat Sterilizer 

Learn More 


TS – GMP Terminal Sterilizer

Learn More 


UCW – GMP Utensils and Containers Washer

Learn More 


UCW – GMP Utensils and Containers Washer

Learn More 


TD – GMP Tray Dryer

Learn More 


CPE – GMP Closure Processing Equipment 

Learn More 


CPE – GMP Closure Processing Equipment 

Learn More 


NEBULA – GLP Steam Autoclave 

Learn More 


AQUA – GLP Glassware Washer

Learn More 


AQUA – GLP Glassware Washer

Learn More 


Certified processes & advanced quality

LAST Technology’s aim is to exceed and develop new solutions for a greater process safety and productivity, in compliance with the most updated international requirements and guidelines

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue